A clinical trial of Unani medicine in the disease of Melasma.

A Single-blind Standard Controlled Randomized clinical trial of Unani formulation in the management of Kalaf (Melasma). - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/068821

Enrollment

Registered

2024-06-12

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Paste of Rewand Chini: Paste of Rewand Chini for local application followed by 2mg sunscreen of SPF30 per cm sq of skin (every 2 hourly) for 6 weeks. Control Intervention1: Paste of 4%

Eligibility

Inclusion criteria

Inclusion criteria: Age- 18 years and above. Both male and female patients. All skin types (Fitzpatrick I to VI). Patients who signed the written consent form. Epidermal and mixed pattern of melasma.

Exclusion criteria

Exclusion criteria: Patients below 18 years. Patient with systemic disease eg: DM, Malignancy, Thyroid dysfunction, CKD, and TB (as per history and clinical examination). History of hypersensitivity reaction to drugs. Patients who were not willing to sign the consent form or remain absent during the study. Pregnant and Lactating mothers. Women who are on OCPs (progesterone).

Design outcomes

Primary

Measure	Time frame
Modified Melasma Area and Severity Index score (mMASI score). Melasma Quality of Life scale (MelasQoL) Photographs (without using filters) Timepoint: 15th, 30th, 45th day	—

Secondary

Measure	Time frame
Fairness, Glow, and ShiningTimepoint: 15th, 30th, 45th day	—

Countries

India

Contacts

Public ContactSafiya Naiyar

Ajmal Khan Tibbia College

aqdas2005@gmail.com9412329198

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026